Shanghai Medicilon Inc. (SHA:688202)

Market Cap	9.22B +113.3%
Revenue (ttm)	1.08B +9.6%
Net Income	-231.86M
EPS	-1.72
Shares Out	131.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,488,206
Average Volume	4,262,041
Open	69.50
Previous Close	70.07
Day's Range	67.84 - 70.68
52-Week Range	27.69 - 84.70
Beta	0.98
RSI	59.73
Earnings Date	Apr 23, 2026

About Shanghai Medicilon

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation services, as well as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,717
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688202

Financial Performance

In 2024, Shanghai Medicilon's revenue was 1.04 billion, a decrease of -24.01% compared to the previous year's 1.37 billion. Losses were -330.85 million, 896.2% more than in 2023.